G1 Therapeutics, Inc.
Clinical trials sponsored by G1 Therapeutics, Inc., explained in plain language.
-
Could a bone marrow shield boost lung cancer therapy?
Disease control CompletedThis study tested whether adding a drug called trilaciclib to standard chemotherapy and immunotherapy could protect the bone marrow and improve treatment effectiveness in 107 people with newly diagnosed extensive-stage small cell lung cancer. Participants received either trilacic…
Phase: PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated May 02, 2026 15:32 UTC
-
Could a bone marrow shield make chemo safer for lung cancer patients?
Disease control CompletedThis study tested a drug called trilaciclib given before chemotherapy to people with advanced small cell lung cancer. The goal was to see if it could protect bone marrow and the immune system from damage caused by chemo, reducing side effects like low white blood cell counts. The…
Phase: PHASE1, PHASE2 • Sponsor: G1 Therapeutics, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC